The company anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, thes...

In the latest trading session, Pfizer (PFE) closed at $25.23, marking a -1.33% move from the previous day.

Pfizer's share price struggles despite a strong asset portfolio and $10 billion annual R&D investment, with significant Seagen acquisition integration ongoing. Q3 2024 results show 32% YoY revenue ...

I upgrade Pfizer to "Strong Buy" due to its undervaluation, strong pipeline, and operational growth despite recent stock price declines. Pfizer's Q3 FY2024 earnings showed significant revenue and E...

Despite Pfizer's (PFE 0.23%) recent struggles with falling earnings and a bid by an activist investor to unseat its leadership, the pharma juggernaut is still actively advancing its core priorities...

Leading vaccine makers like Eli Lilly and Co. NYSE: LLY, Pfizer Inc. NYSE: PFE, and AstraZeneca plc NASDAQ: AZN may have faded from the spotlight since the peak of the COVID-19 pandemic, but now th...

One stock that just can't seem to catch a break of late is Pfizer (PFE 0.23%). Even though it posted some decent earnings numbers, investors can't shake the fear that the business is facing dauntin...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug spending in the U.S. climbed more than 8% to reach $406 billion.

Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% ...

The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years at the company.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief S...

Is It Time to Sell Eli Lilly and Pfizer Stocks?

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis of b...

I have selected Pfizer and Verizon as my top two high dividend yield companies to invest in for November 2024. Both pay an attractive Dividend Yield [FWD] of 6.14% (Pfizer) and 6.58% (Verizon) and ...